Oncolytics Biotech® Inc. Announces 2013 Year End Results

CALGARY, March 13, 2014 /PRNewswire/ – Oncolytics Biotech Inc. (TSX:ONC,
NASDAQ:ONCY) (“Oncolytics” or the “Company”) today announced its
financial results and operational highlights for the year ended
December 31, 2014.

“In 2013, we reported data from a number of clinical studies, which
included our first data correlating specific biomarkers with survival
in NSCLC lung cancer patients and culminated with the reporting of our
first randomized data in head and neck cancer,” said Dr. Brad Thompson,
President and CEO of Oncolytics. “Our randomized clinical program
continues to move ahead with six sponsored studies currently enrolling
patients in a range of indications. Each of these studies will advance
in parallel with our ongoing head and neck program which we are
currently in the process of designing a follow-on registration study
for discussion with regulators.”

Selected Highlights

Since January 1, 2013, specific highlights announced by the Company
include:

Clinical Trial Results

• Top-line data for the endpoints in a double blinded, randomized clinical
  study examining REOLYSIN^® in combination with carboplatin and paclitaxel in patients with
  second-line platinum-refractory, taxane-naïve head and neck cancers
  (REO 018). An analysis was performed on an intent-to-treat basis of 118 patients
  with loco-regional head and neck cancer, with or without metastases.
  Patients in the control arm were treated with carboplatin and
  paclitaxel, while patients in the test arm were treated with
  carboplatin, paclitaxel and REOLYSIN. The analysis showed a median
  progression free survival (PFS) of 94 days (13.4 weeks) in the test arm
  (n=62), versus 50 days (7.1 weeks) in the control arm (n=56). The test
  arm maintained a PFS benefit over the control arm through five cycles
  of therapy. An analysis of 88 loco-regional patients that did not
  receive additional therapy following discontinuation of study treatment
  showed a median overall survival (OS) of 150 days (21.4 weeks) in the
  test arm (n=50), versus 115 days (16.4 weeks) in the control arm
  (n=38). REOLYSIN was deemed safe and well-tolerated by patients. The
  side effects experienced by patients in the test arm of the study were
  consistent with expectations based on outcomes of earlier clinical
  studies using REOLYSIN. Patients on the test arm of the study
  experienced a higher incidence of flu-like symptoms consistent with
  treatment with a virus, most commonly mild fever, chills, nausea and
  diarrhea, on both a per-patient and a per-cycle basis. Fewer patients
  required dose reductions of paclitaxel due to neuropathy or
  neurotoxicity on the test arm than the control arm (zero in the test
  arm versus six in the control arm; p=0.028). On this basis, the Company
  intends to explore the potential chemoprotective and neuroprotective
  properties of REOLYSIN in future clinical studies;

• Positive final results from a U.S. Phase 2 study examining the use of
  REOLYSIN in combination with carboplatin and paclitaxel in patients
  with stage IV non-small cell lung cancer (NSCLC) with Kras or EGFR-activated tumors (REO 016). Response evaluation for 36
  evaluable patients showed 11 partial responses (PR) (30%) (EGFR
  amplified, five; BRAF two; Kras, three; EGFR mutated, one), 21 stable disease (SD), and four
  progressive disease (PD). The data also correlated a number of
  molecular abnormalities with best response, PFS and one-year survival.
  Current data in these patients demonstrates that 20 of 36 evaluable
  patients (56%) survived a year or more. There were 13 patients with
  only EGFR mutations or amplifications, of whom nine (69.2%) survived a
  year or longer. Four of four (100%) patients with BRAF and EGFR
  amplification survived a year or longer;

• Final tumor response and PFS data from a U.S. Phase 2 clinical trial in
  patients with squamous cell carcinoma of the lung (SCCLC) using
  intravenous administration of REOLYSIN in combination with carboplatin
  and paclitaxel (REO 021). Of the 25 evaluable patients who had more
  than one cycle of therapy, 23 (92%) exhibited overall tumor shrinkage.
  When evaluated for best response, which is the best percentage response
  recorded on study compared to baseline, 10 patients (40%) had PR, while
  a further 14 (56%) showed SD, and one (4%), had PD. Using RECIST
  criteria to evaluate best overall response, 10 patients (40%) had PRs,
  12 (48%) showed SD and three (12%), had PD.  31.8% of patients with
  sufficient follow up had a PFS greater than six months;

• Reaching the stage 1 endpoint in a U.S. Phase 2 clinical trial in
  patients with metastatic melanoma (REO 020) after only 14 patients were
  enrolled.  The primary objective of this Phase 2 trial was to assess
  the antitumor effect of the treatment regimen in the study population
  in terms of objective response rates. The secondary objectives were to
  assess progression-free survival and overall survival for the treatment
  regimen; the disease control rate (complete response (CR) plus PR plus
  SD) and duration, and to assess the safety and tolerability of the
  treatment regimen in the study population.  Three of the 14 patients
  exhibited a PR, and an additional seven patients had SD for a disease
  control rate of 71.5%; and

• Positive preliminary results from a Phase 1 study examining the
  intravenous administration of REOLYSIN in combination with FOLFIRI in
  patients with metastatic colorectal cancer (REO 022) in a poster
  presentation at the ASCO Gastrointestinal Cancers Symposium. Of the 18
  patients evaluable for response there was one PR and nine had SD. The
  combined overall PFS of FOLFIRI-naïve and FOLFIRI-failed patients was
  7.4 months. The authors concluded that the combination of REOLYSIN and
  FOLFIRI was safe and well tolerated and resulted in disease control in
  the majority of evaluable patients, including patients that had
  previously progressed on Irinotecan.

Financial

• At December 31, 2013 the Company reported $27.2 million in cash, cash
  equivalents and short-term investments; and

• Subsequent to year end, entry into a share purchase agreement with
  Lincoln Park Capital Fund, LLC that will provide an initial investment
  in Oncolytics of US$1.0 million and make available additional periodic
  investments of up to US$25.0 million over a 30-month term.

ONCOLYTICS BIOTECH INC.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
as at				December 31, 2013 $			December 31, 2012 $
Assets
Current assets
Cash and cash equivalents				25,220,328			19,323,541
Short-term investments				2,001,644			1,969,228
Accounts receivable				105,853			44,979
Prepaid expenses				361,743			331,094
Total current assets				27,689,568			21,668,842
Non-current assets
Property and equipment				532,459			409,248
Total non-current assets				532,459			409,248
Total assets				28,222,027			22,078,090
Liabilities And Shareholders’ Equity
Current Liabilities
Accounts payable and accrued liabilities				6,008,661			7,291,310
Total current liabilities				6,008,661			7,291,310
Shareholders’ equity
Share capital
	Authorized: unlimited
	Issued:  December 31, 2013 – 84,803,818
	December 31, 2012 – 76,710,285			228,612,564			198,155,091
Warrants				376,892			376,892
Contributed surplus				24,491,212			24,126,265
Accumulated other comprehensive loss				79,698			(57,115)
Accumulated deficit				(231,347,000)			(207,814,353)
Total shareholders’ equity				22,213,366			14,786,780
Total liabilities and equity				28,222,027			22,078,090

ONCOLYTICS BIOTECH INC.
CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
For the years ending December 31,				2013 $			2012 $			2011 $
Expenses
Research and development				18,506,064			31,402,625			23,386,685
Operating				5,392,660			5,285,425			5,334,582
Loss before the following				(23,898,724)			(36,688,050)			(28,721,267)
Write down of asset available for sale				—			—			(735,681)
Change in fair value of warrant liability				—			—			36,000
Interest				371,485			345,003			416,247
Loss before income taxes				(23,527,239)			(36,343,047)			(29,004,701)
Income tax expense				(5,408)			(30,474)			(40,000)
Net loss				(23,532,647)			(36,373,521)			(29,044,701)
Other comprehensive income items that may be reclassified to net loss
	Translation adjustment			136,813			60,386			39,159
Net comprehensive loss				(23,395,834)			(36,313,135)			(29,005,542)
Basic and diluted loss per common share				(0.28)			(0.48)			(0.41)
Weighted average number of shares (basic and diluted)				83,530,981			76,102,062			70,911,526

ONCOLYTICS BIOTECH INC.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
			Share Capital $		Warrants $		Contributed Surplus $		Accumulated Other Comprehensive Income $		Accumulated Deficit $		Total $
As at December 31, 2010			155,439,610		4,108,652		19,399,489		(156,660)		(142,396,131)		36,394,960
Net loss and comprehensive income			—		—		—		39,159		(29,044,701)		(29,005,542)
Exercise of warrants			21,487,080		(1,455,025)		—		—		—		20,032,055
Exercise of stock options			355,876		—		(62,473)		—		—		293,403
Share based compensation			—		—		1,805,503		—		—		1,805,503
As at December 31, 2011			177,282,566		2,653,627		21,142,519		(117,501)		(171,440,832)		29,520,379
Net loss and comprehensive income			—		—		—		60,386		(36,373,521)		(36,313,135)
Issued, pursuant to a bought deal financing			19,386,903		376,892		—		—		—		19,763,795
Expiry of warrants			—		(2,653,627)		2,653,627		—		—		—
Exercise of stock options			1,485,622		—		(400,632)		—		—		1,084,990
Share based compensation			—		—		730,751		—		—		730,751
As at December 31, 2012			198,155,091		376,892		24,126,265		(57,115)		(207,814,353)		14,786,780
Net loss and comprehensive income			—		—		—		136,813		(23,532,647)		(23,395,834)
Issued, pursuant to a bought deal financing			30,218,796		—		—		—		—		30,218,796
Expiry of warrants			—		—		—		—		—		—
Exercise of stock options			238,677		—		(59,437)		—		—		179,240
Share based compensation			—		—		424,384		—		—		424,384
As at December 31, 2013			228,612,564		376,892		24,491,212		79,698		(231,347,000)		22,213,366

  

ONCOLYTICS BIOTECH INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the years ending December 31,				2013 $			2012 $			2011 $
Operating Activities
Net loss for the year				(23,532,647)			(36,373,521)			(29,044,701)
	Amortization – property and equipment			131,623			109,275			92,590
	Share based compensation			424,384			730,751			1,805,503
	Change in fair value of warrant liability			—			—			(36,000)
	Write down of asset available for sale			—			—			735,681
	Unrealized foreign exchange loss			(89,721)			89,890			115,234
Net change in non-cash working capital				(1,374,172)			1,187,967			3,790,510
Cash used in operating activities				(24,440,533)			(34,255,638)			(22,541,183)
Investing Activities
Acquisition of property and equipment				(254,834)			(126,412)			(257,790)
Redemption (purchase) of short-term investments				(32,416)			(32,441)			1,672,459
Cash provided by (used in) investing activities				(287,250)			(158,853)			1,414,669
Financing Activities
Proceeds from exercise of stock options and warrants				179,240			1,084,990			14,824,658
Proceeds from public offering				30,218,796			19,763,795			—
Cash provided by financing activities				30,398,036			20,848,785			14,824,658
Increase (decrease) in cash				5,670,253			(13,565,706)			(6,301,856)
Cash and cash equivalents, beginning of year				19,323,541			32,918,751			39,296,682
Impact of foreign exchange on cash and cash equivalents				226,534			(29,504)			(76,075)
Cash and cash equivalents, end of year				25,220,328			19,323,541			32,918,751

To view the Company’s Fiscal 2013 Consolidated Financial Statements,
related Notes to Consolidated Financial Statements, and Management’s
Discussion and Analysis, please see the Company’s annual filings which
will be available on www.sedar.com and on www.oncolyticsbiotech.com/for-investors/financials.

About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN,
its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including the Company’s belief as
to the potential of REOLYSIN as a cancer therapeutic; the Company’s
expectations as to the success of its research and development programs
in 2014 and beyond, the Company’s planned operations, the value of the
additional patents and intellectual property; the Company’s
expectations related to the applications of the patented technology;
the Company’s expectations as to adequacy of its existing capital
resources; the design, timing, success of planned clinical trial
programs; and other statements related to anticipated developments in
the Company’s business and technologies involve known and unknown risks
and uncertainties, which could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
efficacy of REOLYSIN as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company’s ability to
successfully commercialize REOLYSIN, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to
the regulatory process and general changes to the economic environment.
Investors should consult the Company’s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable
laws.

SOURCE Oncolytics Biotech Inc.